The pharmaceutical wholesaler SIA “Berlin-Chemie/Menarini Baltic” worked with a turnover of 11.853 million euros last year, which is 11.3% more than a year earlier, while the company’s profit increased by 29.5% – up to 384,615 euros, according to “Firmas. lv” information.
The management report of the financial statement states that the company achieved its sales targets last year. In the opinion of the management, the financial position of “Berlin-Chemie/Menarini Baltic” is stable.
The management emphasizes that “Berlin-Chemie/Menarini Baltic” also plans to supply patients with medicines and medical devices in new therapeutic groups in the future.
The main task of the future development plan is to maintain the loyalty of existing customers and increase the turnover of new products, according to the report.
“Berlin-Chemie/Menarini Baltic” in Latvia mainly offers prescription drugs for the treatment of patients with cardiovascular system, thyroid gland and diabetes, rheumatism and COPD. The company’s assortment also includes over-the-counter medications for digestion, painkillers, anti-inflammatory and urological products.
In 2021, “Berlin-Chemie/Menarini Baltic” worked with a turnover of 10.654 million euros and a profit of 297,019 euros.
The company was registered in 1998, and its share capital is 2,845 euros. “Berlin-Chemie/Menarini Baltic” belongs to the “Berlin-Chemie” company of the international “Menarini” group through a Lithuanian company of the same name.
Source: LETA
2023-05-31 13:49:07
#turnover #drug #wholesaler #BerlinChemieMenarini #Baltic #increased #year
